Introduction {#section1-1533034617712396}
============

Renal cell carcinoma, one of the most malignant tumors, affects men more frequently than women and constitutes nearly 90% of all kidney tumors.^[@bibr1-1533034617712396]^ The incidence of renal cell carcinoma varies geographically: the highest level is recorded in Europe, North America, and Australia, the lowest in Africa, India, China, and Japan.^[@bibr1-1533034617712396]^ Diagnosis of renal cell carcinoma at an early stage is challenging, but it can provide the best chance for cure.^[@bibr2-1533034617712396]^ Renal cell carcinoma, a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing Von Hippel-Lindau/hypoxia inducible factor (VHL/HIF pathway alterations and the subsequent upregulation of HIF-responsive genes, such as vascular endothelial growth factor \[VEGF\]).^[@bibr3-1533034617712396]^

Vascular endothelial growth factor, an important signaling proteins involved in angiogenesis, can influence on the development of physiological and pathological tissue.^[@bibr4-1533034617712396]^ Angiogenesis is an essential physiological process, and it is an important factor in disease pathogenesis. Vascular endothelial growth factor pathway is reported to play a conspicuous role in the growth and progression of human cancers, such as renal cell carcinoma.^[@bibr5-1533034617712396][@bibr6-1533034617712396]--[@bibr7-1533034617712396]^ VEGF +405G\>C, VEGF −634G\>C, VEGF −460T\>C, VEGF +936C\>T, VEGF −2578 C\>A, VEGF −1154 G\>A, VEGF +1612 G\>A gene polymorphisms were the important gene types for VEGF. The current evidences indicate that VEGF +405G\>C, VEGF −634G\>C, VEGF −460T\>C, VEGF +936C\>T, VEGF −2578 C\>A, VEGF −1154 G\>A, and VEGF +1612 G\>A gene polymorphisms might take part in the pathogenesis of carcinogenesis. This meta-analysis was performed to assess the relationship between VEGF +405G\>C, VEGF −634G\>C, VEGF −460T\>C, VEGF +936C\>T, VEGF −2578 C\>A, VEGF −1154 G\>A, VEGF +1612 G\>A gene polymorphisms and renal cell carcinoma risk.

Materials and Methods {#section2-1533034617712396}
=====================

Search Strategy {#section3-1533034617712396}
---------------

The relevant investigation were searched and included from the databases of PubMed, Embase, and Web of Science, on July 1, 2016. The retrieval strategy of "(vascular endothelial growth factor OR VEGF) AND (renal cell carcinoma OR renal carcinoma) AND (polymorphism OR polymorphisms)" was entered into these databases mentioned above. The additional reports were identified through references cited in recruited articles.

Inclusion and Exclusion Criteria {#section4-1533034617712396}
--------------------------------

### Inclusion criteria {#section5-1533034617712396}

\(1\) The outcome must be renal cell carcinoma, (2) the study included 2 comparison groups (renal cell carcinoma group vs control group), and (3) report should give the data of VEGF genotype distribution.

### Exclusion criteria {#section6-1533034617712396}

\(1\) Case reports, review articles, and editorials; (2) preliminary result not on VEGF gene polymorphism or renal cell carcinoma; (3) investigating the role of VEGF gene expression to renal cell carcinoma.

Data Extraction {#section7-1533034617712396}
---------------

The following information from each eligible investigation was extracted by 2 investigators independently: first author's surname, year of publication, ethnicity, control source of the control group, and the number of cases and controls for VEGF genotypes. Frequencies of allele of VEGF were calculated for renal cell carcinoma group and control group. When the disagreement was occurred, the results would be resolved by discussion.

Statistical Analysis {#section8-1533034617712396}
--------------------

Cochrane Review Manager Version 5 (Cochrane Library, United Kingdom) was used in this meta-analysis to calculate the extracted data from each report. The pooled statistic was counted using the fixed effects model. However, a random effects model was conducted when the *P* value of heterogeneity test was less than.1. Results were expressed using odds ratios (OR) for dichotomous data. Ninety-five percent confidence intervals (CIs) were also calculated. *P* \<.05 was required for the pooled OR to be statistically significant, and *I* ^2^ was used to test the heterogeneity among the included studies. A χ^2^ test using a web-based program was applied to determine whether the genotype distribution of the control population reported for VEGF +936C\>T conformed to Hardy-Weinberg equilibrium (HWE; *P* \<.05 was considered significant). Sensitivity analysis was performed if HWE disequilibrium existed.

Results {#section9-1533034617712396}
=======

Association of VEGF +405G\>C Gene Polymorphism With Renal Cell Carcinoma Risk {#section10-1533034617712396}
-----------------------------------------------------------------------------

Three studies^[@bibr8-1533034617712396][@bibr9-1533034617712396]--[@bibr10-1533034617712396]^ for the relationship between VEGF +405G\>C gene polymorphism and renal cell carcinoma risk were included in this meta-analysis, and the extracted data were shown in [Table 1](#table1-1533034617712396){ref-type="table"}. We found that VEGF +405G\>CC allele and GG genotype were associated with renal cell carcinoma risk in overall populations, but not in CC genotype (C allele: OR = 1.18, 95% CI: 1.05-1.33, *P* = .004; CC genotype: OR = 1.20, 95% CI: 0.96-1.50, *P* = .12; GG genotype: OR = 0.79, 95% CI: 0.67-0.93, *P* = .004; [Table 2](#table2-1533034617712396){ref-type="table"}).

###### 

General Characteristics of the Included Studies in This Meta-Analysis for VEGF Gene Polymorphism With Renal Cell Carcinoma Risk.

![](10.1177_1533034617712396-table1)

  First Author, Year   Country/District   Ethnicity   Case   Control                                     
  -------------------- ------------------ ----------- ------ --------- ----- ------- ----- ------- ----- -------
  VEGF +405G\>C        CC                 GC          GG     Total     CC    GC      GG    Total         
   Bruyere, 2010       France             Caucasian   8      25        15    48      20    92      86    198
   Saenz-Lopez, 2013   Spain              Caucasian   20     93        101   214     32    118     129   279
   Qin, 2014           China              Asian       146    391       287   824     144   429     410   983
  VEGF −634G\>C        CC                 GC          GG     Total     CC    GC      GG    Total         
   Lu, 2015            China              Asian       79     194       139   412     148   377     299   824
   Shen, 2015          China              Asian       69     170       121   360     63    163     134   360
   Xian, 2015          China              Asian       104    132       30    266     227   256     49    532
   Yang, 2015          Taiwan             Asian       39     90        62    191     67    173     136   376
  VEGF −460T\>C        TT                 TC          CC     Total     TT    TC      CC    Total         
   Bruyere, 2010       France             Caucasian   19     29        1     49      47    109     46    202
   Saenz-Lopez, 2013   Spain              Caucasian   56     111       49    216     77    138     58    273
   Lu, 2015            China              Asian       228    93        91    412     513   168     143   824
  VEGF +936C\>T        TT                 TC          CC     Total     TT    TC      CC    Total         
   Abe, 2002           Japan              Asian       7      41        97    145     3     52      90    145
   Bruyere, 2010       France             Caucasian   1      17        29    47      2     53      141   196
   Saenz-Lopez, 2013   Spain              Caucasian   2      57        156   215     7     73      200   280
   Xian, 2015          China              Asian       69     127       70    266     100   236     196   532
   Yang, 2015          Taiwan             Asian       10     59        122   191     22    121     232   375
   Shen, 2015          China              Asian       55     81        224   360     46    73      240   359
   Lu, 2015            China              Asian       59     91        262   412     105   166     554   825
  VEGF −2578 C\>A      AA                 CA          CC     Total     AA    CA      CC    Total         
   Ajaz, 2011          Pakistan           Asian       32     81        30    143     21    41      44    106
   Saenz-Lopez, 2013   Spain              Caucasian   48     114       54    216     53    142     77    272
   Yang, 2015          Taiwan             Asian       10     75        106   191     23    153     200   376
   Lu, 2015            China              Asian       67     174       171   412     95    332     397   824
   Shen, 2015          China              Asian       61     149       150   360     41    141     178   360
   Xian, 2015          China              Asian       48     119       99    266     64    225     243   532
  VEGF −1154 G\>A                                     AA     AG        GG    Total   AA    AG      GG    Total
   Ricketts, 2009      Polish             Caucasian   47     143       134   324     38    130     146   314
   Bruyere, 2010       France             Caucasian   5      17        27    49      25    83      94    202
   Yang, 2015          Taiwan             Asian       8      52        131   191     21    99      256   376
  VEGF +1612 G\>A      AA                 AG          GG     Total     AA    AG      GG    Total         
   Abe, 2002           Japan              Asian       1      31        113   145     3     33      109   145
   Lu, 2015            China              Asian       49     191       172   412     85    375     365   825
   Shen, 2015          China              Asian       39     170       152   361     30    164     166   360
   Xian, 2015          China              Asian       30     123       113   266     41    243     248   532

Abbreviation: VEGF, vascular endothelial growth factor.

###### 

Meta-Analysis of the Association of VEGF Gene Polymorphism With Renal Cell Carcinoma Risk.

![](10.1177_1533034617712396-table2)

  Genetic Contrasts   Group and Subgroups   Studies Number   Q Test *P* Value   Model Selected     OR (95% CI)        *P* Value
  ------------------- --------------------- ---------------- ------------------ ------------------ ------------------ -----------
  VEGF +405G\>C                                                                                                       
   C vs G             Overall               3                .11                Fixed              1.18 (1.05-1.33)   .004
  Asian               1                     --               Fixed              1.23 (1.08-1.41)   .002               
  Caucasian           2                     .08              Random             1.14 (0.72-1.79)   .58                
   CC vs GC+GG        Overall               3                .25                Fixed              1.20 (0.96-1.50)   .12
  Asian               1                     --               Fixed              1.25 (0.98-1.61)   .08                
  Caucasian           2                     .14              Fixed              1.00 (0.61-1.63)   .99                
   GG vs GC+CC        Overall               3                .19                Fixed              0.79 (0.67-0.93)   .004
  Asian               1                     --               Fixed              0.75 (0.62-0.90)   .003               
  Caucasian           2                     .15              Fixed              0.91 (0.67-1.25)   .57                
  VEGF −634G\>C                                                                                                       
   C vs G             Asian                 4                .35                Fixed              1.05 (0.95-1.16)   .35
   CC vs GC+GG        Asian                 4                .57                Fixed              1.03 (0.86-1.22)   .77
   GG vs GC+CC        Asian                 4                .57                Fixed              0.91 (0.77-1.07)   .23
  VEGF −460T\>C                                                                                                       
   T vs C             Overall               3                .0003              Random             1.09 (0.69-1.72)   .72
  Asian               1                     --               Fixed              0.76 (0.63-0.91)   .003               
  Caucasian           2                     .002             Random             1.38 (0.61-3.12)   .44                
   TT vs TC+CC        Overall               3                .02                Random             1.02 (0.63-1.65)   .93
  Asian               1                     --               Fixed              0.75 (0.59-0.95)   .02                
  Caucasian           2                     .03              Random             1.31 (0.57-3.00)   .53                
   CC vs TC+TT        Overall               3                .01                Random             0.93 (0.47-1.84)   .83
  Asian               1                     --               Fixed              1.35 (1.01-1.81)   .05                
  Caucasian           2                     .005             Random             0.32 (0.02-5.65)   .44                
  VEGF +936C\>T                                                                                                       
   T vs C             Overall               7                .13                Fixed              1.16 (1.05-1.29)   .004
  Asian               5                     .13              Fixed              1.18 (1.06-1.32)   .003               
  Caucasian           2                     .14              Fixed              1.02 (0.76-1.39)   .87                
   TT vs TC+CC        Overall               7                .48                Fixed              1.25 (1.02-1.52)   .03
  Asian               5                     .56              Fixed              1.27 (1.04-1.56)   .02                
  Caucasian           2                     .23              Fixed              0.56 (0.15-2.05)   .38                
   CC vs TC+TT        Overall               7                .12                Fixed              0.86 (0.75-0.98)   .03
  Asian               5                     .09              Random             0.87 (0.70-1.07)   .18                
  Caucasian           2                     .19              Fixed              0.93 (0.66-1.30)   .66                
  VEGF −2578 C\>A                                                                                                     
   A vs C             Overall               6                .15                Fixed              1.26 (1.15-1.38)   \<.00001
  Asian               5                     .12              Fixed              1.28 (1.16-1.42)   \<.00001           
  Caucasian           1                     --               Fixed              1.13 (0.88-1.45)   .35                
   AA vs CA+CC        Overall               6                .63                Fixed              1.39 (1.16-1.67)   .0004
  Asian               5                     .59              Fixed              1.44 (1.18-1.76)   .0004              
  Caucasian           1                     --               Fixed              1.18 (0.76-1.83)   .46                
   CC vs CA+AA        Overall               6                .05                Random             0.75 (0.61-0.92)   .006
  Asian               5                     .03              Random             0.73 (0.58-0.93)   .01                
  Caucasian           1                     --               Fixed              0.84 (0.56-1.27)   .41                
  VEGF −1154 G\>A                                                                                                     
   A vs G             Overall               3                .23                Fixed              1.04 (0.88-1.24)   .63
  Asian               1                     --               Fixed              0.94 (0.68-1.29)   .70                
  Caucasian           2                     .13              Fixed              1.09 (0.89-1.34)   .41                
   AA vs GA+GG        Overall               3                .49                Fixed              1.04 (0.72-1.51)   .82
  Asian               1                     --               Fixed              0.74 (0.32-1.70)   .48                
  Caucasian           2                     .45              Fixed              1.14 (0.76-1.73)   .53                
   GG vs GA+AA        Overall               3                .27                Fixed              0.95 (0.76-1.18)   .63
  Asian               1                     --               Fixed              1.02 (0.70-1.49)   .90                
  Caucasian           2                     .12              Fixed              0.91 (0.69-1.20)   .49                
  VEGF +1612 G\>A                                                                                                     
   A vs G             Asian                 4                .59                Fixed              1.12 (1.00-1.25)   .05
   AA vs GA+GG        Asian                 4                .56                Fixed              1.27 (0.99-1.64)   .06
   GG vs GA+AA        Asian                 4                .76                Fixed              0.89 (0.77-1.04)   .14

Abbreviations: OR, odds ratio; VEGF, vascular endothelial growth factor.

In the subgroup analysis by ethnicity, this meta-analysis indicated that VEGF +405G\>CC allele and GG genotype were associated with renal cell carcinoma risk in Asian population but not in CC genotype ([Table 2](#table2-1533034617712396){ref-type="table"}). However, VEGF +405G\>C gene polymorphism was not associated with renal cell carcinoma susceptibility in Caucasian population ([Table 2](#table2-1533034617712396){ref-type="table"}).

Association of VEGF −634G\>C Gene Polymorphism With Renal Cell Carcinoma Risk {#section11-1533034617712396}
-----------------------------------------------------------------------------

Four studies^[@bibr11-1533034617712396][@bibr12-1533034617712396][@bibr13-1533034617712396]--[@bibr14-1533034617712396]^ for the relationship between VEGF −634G\>C gene polymorphism and renal cell carcinoma risk were included in this meta-analysis, and all studies were performed in Asian population ([Table 1](#table1-1533034617712396){ref-type="table"}). We found that VEGF −634G\>C gene polymorphism was not associated with renal cell carcinoma risk in Asian population ([Table 2](#table2-1533034617712396){ref-type="table"}).

Association of VEGF −460C \>T Gene Polymorphism With Renal Cell Carcinoma Risk {#section12-1533034617712396}
------------------------------------------------------------------------------

Three studies^[@bibr8-1533034617712396],[@bibr9-1533034617712396],[@bibr11-1533034617712396]^ for the relationship between VEGF −460C\>T gene polymorphism and renal cell carcinoma risk were included in this meta-analysis, and the extracted data were shown in [Table 1](#table1-1533034617712396){ref-type="table"}. We found that VEGF −460C\>T gene polymorphism was not associated with renal cell carcinoma risk in overall populations ([Table 2](#table2-1533034617712396){ref-type="table"}).

In the subgroup analysis by ethnicity, this meta-analysis indicated that, in Asian population, VEGF −460C\>TT allele and TT genotype were associated with renal cell carcinoma risk but not in CC genotype ([Table 2](#table2-1533034617712396){ref-type="table"}). However, VEGF −460C\>T gene polymorphism was not associated with renal cell carcinoma risk in Caucasian population ([Table 2](#table2-1533034617712396){ref-type="table"}).

Association of VEGF +936C\>T Gene Polymorphism With Renal Cell Carcinoma Risk {#section13-1533034617712396}
-----------------------------------------------------------------------------

Seven studies^[@bibr8-1533034617712396],[@bibr9-1533034617712396],[@bibr11-1533034617712396][@bibr12-1533034617712396][@bibr13-1533034617712396][@bibr14-1533034617712396]--[@bibr15-1533034617712396]^ for the relationship between VEGF +936C\>T gene polymorphism and renal cell carcinoma risk were included in this meta-analysis, and the extracted data were shown in [Table 1](#table1-1533034617712396){ref-type="table"}. We found that VEGF +936C\>T gene polymorphism was associated with renal cell carcinoma risk in overall populations (T allele: OR = 1.16, 95% CI: 1.05-1.29, *P* = .004; TT genotype: OR = 1.25, 95% CI: 1.02-1.52, *P* = .03; CC genotype: OR = 0.86, 95% CI: 0.75-0.98, *P* = .03; [Figure 1](#fig1-1533034617712396){ref-type="fig"} and [Table 2](#table2-1533034617712396){ref-type="table"}).

![Association between VEGF +936C\>T gene polymorphism and renal cell carcinoma risk (overall populations).](10.1177_1533034617712396-fig1){#fig1-1533034617712396}

In the subgroup analysis by ethnicity, this meta-analysis indicated that, in Asian population, VEGF +936C\>TT allele and TT genotype were associated with renal cell carcinoma risk but not in CC genotype ([Table 2](#table2-1533034617712396){ref-type="table"}). However, VEGF +936C\>T gene polymorphism was not associated with renal cell carcinoma risk in Caucasian population ([Table 2](#table2-1533034617712396){ref-type="table"}).

Sensitivity analysis according to genotype distribution of the control population reported for VEGF +936C\>T gene polymorphism conformed to HWE for the relationship between VEGF +936C\>T gene polymorphism and renal cell carcinoma risk was performed. Two studies^[@bibr11-1533034617712396],[@bibr12-1533034617712396]^ were not in HWE. We found that T allele, TT genotype, and CC genotype were not associated with renal cell carcinoma risk (T allele: OR = 1.15, 95% CI: 1.00-1.32, *P* = .05; TT genotype: OR = 1.34, 95% CI: 0.99-1.80, *P* = .05; CC genotype: OR = 0.89, 95% CI: 0.76-1.05, *P* = .17). The results from sensitivity analysis according to HWE were not same as those from nonsensitivity analysis.

Association of VEGF −2578 C\>A Gene Polymorphism With Renal Cell Carcinoma Risk {#section14-1533034617712396}
-------------------------------------------------------------------------------

Six studies^[@bibr9-1533034617712396],[@bibr11-1533034617712396][@bibr12-1533034617712396][@bibr13-1533034617712396]--[@bibr14-1533034617712396],[@bibr16-1533034617712396]^ for the relationship between VEGF −2578 C\>A gene polymorphism and renal cell carcinoma risk were included in this meta-analysis, and the extracted data were shown in [Table 1](#table1-1533034617712396){ref-type="table"}. We found that VEGF −2578 C\>A gene polymorphism was associated with renal cell carcinoma risk in overall populations (A allele: OR = 1.26, 95% CI: 1.15-1.38, *P* \> .00001; AA genotype: OR = 1.39, 95% CI: 1.16-1.67, *P* = .0004; CC genotype: OR = 0.75, 95% CI: 0.61-0.92, *P* = .006; [Figure 2](#fig2-1533034617712396){ref-type="fig"} and [Table 2](#table2-1533034617712396){ref-type="table"}).

![Association between VEGF −2578 C\>A gene polymorphism and renal cell carcinoma risk (overall populations).](10.1177_1533034617712396-fig2){#fig2-1533034617712396}

In the subgroup analysis by ethnicity, this meta-analysis indicated that, in Asian population, VEGF −2578 C\>A gene polymorphism was associated with renal cell carcinoma risk ([Table 2](#table2-1533034617712396){ref-type="table"}). However, VEGF −2578 C\>A gene polymorphism was not associated with renal cell carcinoma risk in Caucasian population ([Table 2](#table2-1533034617712396){ref-type="table"}).

Association of VEGF −1154 G\>A Gene Polymorphism With Renal Cell Carcinoma Risk {#section15-1533034617712396}
-------------------------------------------------------------------------------

Three studies^[@bibr8-1533034617712396],[@bibr14-1533034617712396],[@bibr17-1533034617712396]^ for the relationship between VEGF −1154 G\>A gene polymorphism and renal cell carcinoma risk were included in this meta-analysis, and the extracted data were shown in [Table 1](#table1-1533034617712396){ref-type="table"}. We found that VEGF −1154 G\>A gene polymorphism was not associated with renal cell carcinoma risk in overall populations ([Table 2](#table2-1533034617712396){ref-type="table"}).

In the subgroup analysis by ethnicity, this meta-analysis indicated that, in Asian population, VEGF −1154 G\>A gene polymorphism was not associated with renal cell carcinoma risk ([Table 2](#table2-1533034617712396){ref-type="table"}). Furthermore, VEGF −1154 G\>A gene polymorphism was also not associated with renal cell carcinoma risk in Caucasian population ([Table 2](#table2-1533034617712396){ref-type="table"}).

Association of VEGF +1612 G\>A Gene Polymorphism With Renal Cell Carcinoma Risk {#section16-1533034617712396}
-------------------------------------------------------------------------------

Four studies^[@bibr11-1533034617712396][@bibr12-1533034617712396]--[@bibr13-1533034617712396],[@bibr15-1533034617712396]^ for the relationship between VEGF +1612 G\>A gene polymorphism and renal cell carcinoma risk were included in this meta-analysis, and all studies were performed in Asian population ([Table 1](#table1-1533034617712396){ref-type="table"}). We found that VEGF +1612 G\>A gene polymorphism was not associated with renal cell carcinoma risk in Asian population ([Table 2](#table2-1533034617712396){ref-type="table"}).

Discussion {#section17-1533034617712396}
==========

In this meta-analysis, we found that VEGF +405G\>CC allele and GG genotype were associated with renal cell carcinoma risk, but CC genotype not in Asian population and in overall populations. However, VEGF +405G\>C gene polymorphism was not associated with renal cell carcinoma risk in Caucasians. However, there were only 3 included studies for this meta-analysis (1 for Asians and 2 for Caucasians). The results for the relationship between VEGF +405G\>C gene polymorphism and renal cell carcinoma risk might be less robust. More studies should be performed in the future.

In the meta-analysis for the relationship between VEGF −460T\>C gene polymorphism and renal cell carcinoma risk, we found that VEGF −460T\>C gene polymorphism was associated with renal cell carcinoma risk in Asian population. But, there was only one included studies for Asians, and the results might be less robust. However, VEGF −460T\>C gene polymorphism was associated with renal cell carcinoma risk in Caucasians and in overall populations.

Interestingly, VEGF +936C\>TT allele and TT genotype were found to be associated with renal cell carcinoma risk in Asians and in overall populations, and CC genotype was associated with renal cell carcinoma risk in overall populations. The sample size for overall populations was 7 studies, and the sample size for Asians was 5 studies. We also tested the publication bias for Asians and overall populations and found there was no publication bias for Asians or for overall populations (data not shown). However, VEGF +936C\>T gene polymorphism was not associated with renal cell carcinoma risk in Caucasians, and there were only 2 included studies for the meta-analysis in Caucasians. The results for Caucasians should be confirmed in the future.

Furthermore, we also found that VEGF −2578 C\>A gene polymorphism was associated with renal cell carcinoma risk in Asians and in overall populations. The sample size for overall populations was 6 studies, and the sample size for Asians was 5 studies. We also tested the publication bias for Asians and overall populations and also found there was no publication bias for Asians or for overall populations (data not shown). However, VEGF −2578 C\>A gene polymorphism was not associated with renal cell carcinoma risk in Caucasians, and there was only one included study for the meta-analysis in Caucasians. The results for Caucasians should be retested in further.

This meta-analysis also indicated that VEGF −634G\>C gene polymorphism and VEGF +1612 G\>A gene polymorphism were not associated with renal cell carcinoma risk in Asians. Furthermore, VEGF −1154 G\>A gene polymorphism was not associated with renal cell carcinoma risk in Asians, in Caucasians, and in overall populations. The sample sizes for VEGF −634G\>C gene polymorphism and VEGF +1612 G\>A gene polymorphism were 4, and the sample size for VEGF −1154 G\>A gene polymorphism was 3. More studies should be conducted in the future.

In previous, Zhang *et al* ^[@bibr18-1533034617712396]^ performed a meta-analysis including 5 studies and indicated that the VEGF +936C\>T (including 3 studies), +1612 G\>A (including 1 study), −1154 G\>A (including 2 studies), −460T\>C (including 2 studies), and +405G\>C (including 2 studies) gene polymorphisms were not associated with the risk of renal cell carcinoma, and −2578 C\>A gene polymorphism might be associated with an increased risk of renal cell carcinoma (including 2 studies). The sample sizes in our meta-analysis were larger than those for Zhang *et al*.^[@bibr18-1533034617712396]^ The results from our meta-analysis might be more robust. Furthermore, we first conducted the meta-analysis for the relationship between VEGF −634G\>C gene polymorphism and the risk of renal cell carcinoma (including 4 studies) and reported that VEGF −634G\>C gene polymorphism was not associated with renal cell carcinoma risk in Asians.

Nie *et al* ^[@bibr19-1533034617712396]^ performed a hospital-based case--control study, analyzed peripheral venous blood collected from 100 patients with cutaneous squamous cell carcinoma (cSCC) and 124 healthy controls, and reported that VEGF gene −460 C\>T polymorphism and −1154 G\>A polymorphism may serve as potential genetic markers for the risk and prognosis of cSCC. Rezaei *et al* ^[@bibr20-1533034617712396]^ performed a study aimed to evaluate the impact of VEGF rs3025039 (+936C\>T), rs2010963 (+405C\>G), rs833061 (−460T\>C), rs699947 (−2578C\>A), and rs35569394 (18-bp I/D) polymorphisms on breast cancer (BC) risk in an Iranian population in southeast of Iran and reported that VEGF rs699947 polymorphism may increase the risk of BC development. Bingül *et al* ^[@bibr21-1533034617712396]^ isolated the DNA from peripheral blood leukocytes of 127 patients with papillary thyroid carcinoma (PTC) and 203 healthy controls and reported that VEGF G+405C polymorphism is associated with an increased risk of PTC. In different cancers, the relationship might be different.

However, there were some limitations in our meta-analyses, due to the lack of heterogeneity analysis, sensitivity analysis, and publication bias of the pooling OR. For the result that the sample size of included studies was small, and it was difficult to state that different cancers have different incidence in different population, have you ever considered the prevalence and ethnics.

In conclusion, VEGF +405G\>CC allele, +405G\>C GG genotype, VEGF −2578 C\>A gene polymorphism, VEGF +936C\>TT allele, and VEGF +936C\>T TT genotype were associated with renal cell carcinoma risk in Asian population and in overall populations. Furthermore, VEGF −460T\>C gene polymorphism was associated with renal cell carcinoma risk in Asian population, and CC genotype was associated with renal cell carcinoma risk in overall populations. However, more association studies are required to clarify this relationship further.
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:   cutaneous squamous cell carcinoma
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:   vascular endothelial growth factor.
